Table 1.
Protein- and phospholipid composition of surfactant preparations of different origin.
| Preparation | Origin | SP-B | SP-C | Phospholipids (PL) | Others | Ref. |
|---|---|---|---|---|---|---|
| First-generation synthetic surfactant preparations | ||||||
| Colfosceril (Exosurf®) |
Synthetic | – | – | 13.5 mg/mL (DPPC) |
Hexadecanol Tyloxapol |
[109] |
| Pumactant (ALEC®) |
Synthetic | – | – | 40 mg/mL (DPPC, PG) |
– | [109] |
| Animal-derived surfactant preparations | ||||||
| Poractant Alfa (Curosurf®) |
Minced porcine lung extract | 2–3.7 mg/mM PL |
5–11.6 mg/mM PL | 80 mg/mL |
Tripalmitoylglycerol Palmitic acid |
[109,110] |
| Beractant (Survanta®) |
Minced bovine lung extract | 0–1.3 mg/mM PL |
1–20 mg/mM PL |
25–30 mg/mL |
– | [109,110] |
| Calfactant (Infasurf®) |
Calf lung lavage | 5.4 mg/mM PL |
8.1 mg/mM PL |
35 mg/mL |
– | [109,110] |
| SF-RI I (Alveofact®) |
Bovine lung lavage | 2–5.6 mg/mM PL |
1–12 mg/mM PL |
40 mg/mL |
– | [109] |
| Second-generation synthetic surfactant preparations | ||||||
| Lucinactant (Surfaxin®) |
Synthetic | 19.8 mg/mM PL (KL4) |
– | 30 mg/mL (DPPC, POPG) |
Palmitic acid | [109] |
| CHF5633 (Under clinical investigation, phase II) |
Synthetic | 0.2% (Mini-Bleu) |
1.5% (SP-C33Leu) |
80 mg/mL (DPPC, POPG) |
– | [111,112] |
| Minisurf (Under preclinical investigation) |
Synthetic | 3% (SMB) |
– | DPPC, POPC, POPG | – | [111] |